These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 17553362)

  • 1. [Screening for prostate cancer--what does the evidence show?].
    Borre M; Iversen P
    Ugeskr Laeger; 2007 May; 169(20):1887-8. PubMed ID: 17553362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PSA related screening of prostate cancer. Panic or improvement?].
    Fornara P; Jurczok A
    Aktuelle Urol; 2004 Feb; 35(1):43-8. PubMed ID: 14997414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rural residence and prostate cancer screening with prostate-specific antigen.
    Stamatiou K; Skolarikos A
    Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
    Ito K
    Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
    [No Abstract]   [Full Text] [Related]  

  • 5. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS; Sherin K;
    Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [No evidence that lowered PSA reference levels will help us detect those cases of prostatic cancer that will lead to morbidity and mortality].
    Malmström PU
    Lakartidningen; 2005 Jun 27-Jul 10; 102(26-27):2005; author reply 2005. PubMed ID: 16044760
    [No Abstract]   [Full Text] [Related]  

  • 7. PSA-based screening for prostate cancer. Too many adverse effects.
    Prescrire Int; 2012 Sep; 21(130):215-7. PubMed ID: 23016259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
    Ito K
    Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PSA based screening for prostatic cancer].
    Johansen TE
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357
    [No Abstract]   [Full Text] [Related]  

  • 10. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.
    Hernández J; Thompson IM
    Cancer; 2004 Sep; 101(5):894-904. PubMed ID: 15329895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing.
    Oberaigner W; Horninger W; Klocker H; Schönitzer D; Stühlinger W; Bartsch G
    Am J Epidemiol; 2006 Aug; 164(4):376-84. PubMed ID: 16829552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Based on current knowledge the introduction of the PSA screening for prostatic cancer is unethical].
    Krantz I; Sachs L; Ahlberg BM; Nordin P; Nilstun T
    Lakartidningen; 2005 Sep 5-11; 102(36):2498-500. PubMed ID: 16196436
    [No Abstract]   [Full Text] [Related]  

  • 14. Current status of PSA screening. Early detection of prostate cancer.
    Pickles T
    Can Fam Physician; 2004 Jan; 50():57-63. PubMed ID: 14761105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of publication of US and European prostate cancer screening trials on PSA testing practices.
    Zeliadt SB; Hoffman RM; Etzioni R; Gore JL; Kessler LG; Lin DW
    J Natl Cancer Inst; 2011 Mar; 103(6):520-3. PubMed ID: 21357307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The significance and limitation of prostate specific antigen in the mass screening for prostate cancer].
    Imai K; Yamanaka H
    Nihon Rinsho; 1998 Aug; 56(8):1994-7. PubMed ID: 9750494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer: a review of common underwriting problems, Part 1.
    Richie RC; Swanson JO
    J Insur Med; 2004; 36(3):242-54. PubMed ID: 15495440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Large part of Swedish men PSA tested for early prostatic cancer. Few aware of the disadvantages of the test].
    Bratt O; Grenabo L
    Lakartidningen; 2010 Feb 17-23; 107(7):432-5. PubMed ID: 20384075
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy vs effectiveness in prostate-specific antigen screening.
    Albertsen PC
    J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
    [No Abstract]   [Full Text] [Related]  

  • 20. The Japanese guideline for prostate cancer screening.
    Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
    Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.